MEGAN SIMPSON: Open Payments
NPI 1184145096 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$706 in 30 payments from 14 companies in 2025. Trend: 2023 $911 · 2024 $745 · 2025 $706
Food & beverage: $706
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $175 |
| ABBVIE INC. | 9 | $161 |
| Novo Nordisk Inc | 3 | $79 |
| Novartis Pharmaceuticals Corporation | 2 | $53 |
| PFIZER INC. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $33 |
| Boston Scientific Corporation | 1 | $25 |
| Amgen Inc. | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
Products named: FARXIGA, QULIPTA, Wegovy, UBRELVY, NURTEC ODT, Veozah, CAPLYTA, AIRSUPRA.
Industry payments across NE — which companies pay providers there.
